Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
$ V1 k k! }/ p' ]9 B6 J! p; G' b4 w* d. d- `/ k; Q3 r
5 C1 ^+ G2 M% a7 C/ K& g" t# [- N2 JSub-category:- w3 o! m) x, g5 s3 g
Molecular Targets
2 j2 o. j; V% a% u, u: k
! M! x; |, L0 g H( l& D4 M$ B2 V4 t1 y1 L, Z! b( a
Category:7 M, P7 T/ l. {; D7 Y: j* K
Tumor Biology
6 T3 J U% U- S3 N) Z
9 U: c3 o/ ~$ p( u; Q: w% V' e' }+ I) {7 H; O x" h
Meeting:
. M$ e8 f" A! I1 u2011 ASCO Annual Meeting 8 S7 X- B) s, q2 I' |
4 z" S \2 }: ~' j) t5 r% x1 r! N( {7 a4 D% t
Session Type and Session Title:
5 \7 Q. @7 P- u1 d+ ]Poster Discussion Session, Tumor Biology
+ Y' ~7 ]* Q: \0 `- C5 d
* \% p7 f b0 i! Z+ l2 |, S/ B( i1 c' z1 I# Q }# Z. O$ O
Abstract No:
' Y% r- Z- U. o& r10517
& k" `+ @( C2 H5 q) Q+ d8 I, \& ?6 a6 m4 Q5 K& L7 `
G, R* e( l% L9 `+ x# HCitation:
8 y/ ]" O- m6 F' Z( }J Clin Oncol 29: 2011 (suppl; abstr 10517) $ o4 H D B, S! q4 {
: E' o: ~/ ]! ?( l( V7 I2 j1 B; M& K
4 F9 v/ |: O2 O) s0 F& i+ oAuthor(s):) a& d% f h5 s. U) m' u
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
z& X, K: l+ p
4 R# _# r* u0 o, M, a" e
: C8 l6 L/ V/ }' Y2 `9 a2 \6 F1 O! m6 I- N* m
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 k, j z& `: {0 ]/ w' L, }& ?
% _0 S* c0 P3 v$ m& q) {Abstract Disclosures
4 ^+ W3 n9 g( k5 B1 X# v) R& c% _
# Z( @ f& O! k6 |7 J a4 Y6 x" t( d, J8 {Abstract:
+ n: l" `4 v# m, {& V+ k
+ a' _, Q" o8 A; H2 L7 s& q& j) C) p
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.' J1 ^1 B, y, r3 Y: C
. F# q9 W' M! J7 G3 T
5 s0 z6 ?% d# R( v$ x |